Recent advances in the antiphospholipid antibody syndrome

Shruti Chaturvedi, Keith R. McCrae

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


PURPOSE OF REVIEW: The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent thrombosis and/or obstetrical morbidity in the presence of persistently positive antiphospholipid antibodies. Recent insights into the pathogenesis of APS have begun to elucidate pathophysiology and led to the identification of potential therapeutic interventions. The objective of this review is to examine the advances in this field and highlight the areas of further investigation. RECENT FINDINGS: Several mechanisms of thrombosis and pregnancy loss in APS have been proposed. These include activation of endothelial cells, monocytes, and platelets, and/or inhibition of natural anticoagulant and fibrinolytic systems by antiphospholipid antibodies. However, in many cases the underlying molecular mechanisms and their relevance to the human disorder remain uncertain. New therapeutic agents such as statins, hydroxychloroquine, rituximab, complement inhibitors, and interventions aimed at disruption of intracellular signaling pathways have shown promise in preclinical and clinical studies. SUMMARY: Indefinite anticoagulation remains the mainstay of treatment for thrombotic APS. Despite advances in diagnostic techniques, it remains difficult to predict thrombotic risk in asymptomatic patients with antiphospholipid antibodies. Further mechanistic and clinical studies are needed to predict thrombotic risk and develop improved therapies for this devastating illness.

Original languageEnglish (US)
Pages (from-to)371-379
Number of pages9
JournalCurrent opinion in hematology
Issue number5
StatePublished - Sep 2014
Externally publishedYes


  • antiphospholipid
  • lupus anticoagulant
  • thrombosis
  • β2-glycoprotein I

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Recent advances in the antiphospholipid antibody syndrome'. Together they form a unique fingerprint.

Cite this